Login / Signup

Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.

Samantha ConroyKarl PangIbrahim JubberSyed A HussainDerek J RosarioMarcus G CumberbatchJames W F CattoAidan P Noon
Published in: BJUI compass (2022)
Our single-institution experience suggests that HIVEC and MMC are tolerable and acceptable. Oncological outcomes in this predominantly elderly, pretreated cohort are promising; however, disease progression was higher in patients pretreated with BCG. Further randomised noninferiority trials comparing HIVEC versus BCG in high-risk NMIBC are required.
Keyphrases